Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) gapped down prior to trading on Tuesday . The stock had previously closed at $0.51, but opened at $0.47. Cytori Therapeutics shares last traded at $0.34, with a volume of 6618200 shares.

A number of analysts recently commented on CYTX shares. Maxim Group set a $5.00 price target on Cytori Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th. Zacks Investment Research raised Cytori Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Finally, B. Riley reaffirmed a “hold” rating on shares of Cytori Therapeutics in a research note on Tuesday, November 7th.

The stock has a market capitalization of $12.65, a P/E ratio of -0.40 and a beta of 3.21.

Cytori Therapeutics (NASDAQ:CYTX) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. The business had revenue of $1.77 million during the quarter, compared to the consensus estimate of $2.04 million. Cytori Therapeutics had a negative return on equity of 228.21% and a negative net margin of 367.33%. During the same quarter in the prior year, the company earned ($0.26) earnings per share. analysts predict that Cytori Therapeutics Inc will post -0.62 EPS for the current fiscal year.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Sabby Management LLC boosted its position in Cytori Therapeutics Inc (NASDAQ:CYTX) by 28.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,626,807 shares of the biotechnology company’s stock after purchasing an additional 355,504 shares during the quarter. Sabby Management LLC owned approximately 4.69% of Cytori Therapeutics worth $1,789,000 at the end of the most recent quarter. 7.41% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with's FREE daily email newsletter.